Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of MOR106 in moderate to severe atopic dermatitis
2017-001142-10Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing MOR106 intravenous with Placebo intravenous (2 arms). Started Dec 2017; status: terminated.
02
Drugs
MOR106
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-001142-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001142-10.